Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $43.25, for a total transaction of $237,875.00. Following the completion of the sale, the chairman now directly owns 43,014 shares in the company, valued at approximately $1,860,355.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded up 3.15% during midday trading on Friday, hitting $44.26. 2,123,443 shares of the stock were exchanged. The company’s market capitalization is $5.48 billion. Ionis Pharmaceuticals Inc has a 1-year low of $19.59 and a 1-year high of $57.00. The firm has a 50-day moving average of $41.65 and a 200-day moving average of $42.02.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, February 28th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.53. The firm earned $160.30 million during the quarter, compared to analyst estimates of $97.47 million. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The business’s revenue was up 210.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.59) earnings per share. On average, equities analysts expect that Ionis Pharmaceuticals Inc will post ($0.50) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/04/22/insider-selling-ionis-pharmaceuticals-inc-ions-chairman-sells-5500-shares-of-stock.html.
Several analysts have recently issued reports on IONS shares. Leerink Swann boosted their price target on shares of Ionis Pharmaceuticals from $40.00 to $47.00 and gave the company a “market perform” rating in a research report on Tuesday, December 27th. Laidlaw upped their target price on shares of Ionis Pharmaceuticals from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, December 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, December 27th. BMO Capital Markets upped their target price on shares of Ionis Pharmaceuticals from $61.00 to $68.00 and gave the stock an “outperform” rating in a report on Wednesday, December 28th. Finally, Janney Montgomery Scott reaffirmed a “neutral” rating and set a $54.00 target price (up previously from $50.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, December 28th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $43.74.
Several hedge funds have recently modified their holdings of IONS. HL Financial Services LLC bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $216,000. Commonwealth Equity Services Inc raised its stake in shares of Ionis Pharmaceuticals by 15.8% in the third quarter. Commonwealth Equity Services Inc now owns 19,011 shares of the company’s stock worth $697,000 after buying an additional 2,594 shares in the last quarter. Rothschild Asset Management Inc. raised its stake in shares of Ionis Pharmaceuticals by 8.1% in the third quarter. Rothschild Asset Management Inc. now owns 205,347 shares of the company’s stock worth $7,524,000 after buying an additional 15,353 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $5,305,000. Finally, Aperio Group LLC raised its stake in shares of Ionis Pharmaceuticals by 14.4% in the third quarter. Aperio Group LLC now owns 11,766 shares of the company’s stock worth $431,000 after buying an additional 1,479 shares in the last quarter. 87.76% of the stock is owned by hedge funds and other institutional investors.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.